Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free CORT Stock Alerts

Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics logo
$85.90 -5.98 (-6.51%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$83.66 -2.24 (-2.60%)
As of 06:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CORT vs. ANVS, RPRX, ZTS, JAZZ, and SUPN

Should you buy Corcept Therapeutics stock or one of its competitors? MarketBeat compares Corcept Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "medical" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Corcept Therapeutics had 6 more articles in the media than Annovis Bio. MarketBeat recorded 13 mentions for Corcept Therapeutics and 7 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.88 beat Corcept Therapeutics' score of 0.55 indicating that Annovis Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annovis Bio
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Annovis Bio has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.71N/A
Corcept Therapeutics$761.41M12.11$99.65M$0.35245.43

Annovis Bio presently has a consensus price target of $11.67, indicating a potential upside of 568.58%. Corcept Therapeutics has a consensus price target of $88.83, indicating a potential upside of 3.41%. Given Annovis Bio's higher probable upside, research analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Corcept Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75

Corcept Therapeutics has a net margin of 6.14% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 7.40% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -318.08% -215.47%
Corcept Therapeutics 6.14%7.40%5.76%

Summary

Corcept Therapeutics beats Annovis Bio on 11 of the 15 factors compared between the two stocks.

How does Corcept Therapeutics compare to Royalty Pharma?

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Corcept Therapeutics presently has a consensus target price of $88.83, suggesting a potential upside of 3.41%. Royalty Pharma has a consensus target price of $56.57, suggesting a potential upside of 0.22%. Given Corcept Therapeutics' higher probable upside, research analysts clearly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M12.11$99.65M$0.35245.43
Royalty Pharma$2.38B13.67$770.95M$1.4738.40

Corcept Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Royalty Pharma has a net margin of 33.88% compared to Corcept Therapeutics' net margin of 6.14%. Royalty Pharma's return on equity of 29.25% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics6.14% 7.40% 5.76%
Royalty Pharma 33.88%29.25%14.71%

In the previous week, Corcept Therapeutics had 4 more articles in the media than Royalty Pharma. MarketBeat recorded 13 mentions for Corcept Therapeutics and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.33 beat Corcept Therapeutics' score of 0.55 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Royalty Pharma
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Royalty Pharma beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Zoetis?

Corcept Therapeutics (NASDAQ:CORT) and Zoetis (NYSE:ZTS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Corcept Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M12.11$99.65M$0.35245.43
Zoetis$9.47B3.34$2.67B$6.0312.51

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.14%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics6.14% 7.40% 5.76%
Zoetis 27.80%66.85%18.79%

Corcept Therapeutics presently has a consensus price target of $88.83, suggesting a potential upside of 3.41%. Zoetis has a consensus price target of $123.46, suggesting a potential upside of 63.62%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Zoetis
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.41

In the previous week, Zoetis had 27 more articles in the media than Corcept Therapeutics. MarketBeat recorded 40 mentions for Zoetis and 13 mentions for Corcept Therapeutics. Zoetis' average media sentiment score of 0.57 beat Corcept Therapeutics' score of 0.55 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
17 Very Positive mention(s)
1 Positive mention(s)
21 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Zoetis beats Corcept Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Jazz Pharmaceuticals currently has a consensus target price of $252.88, indicating a potential upside of 6.71%. Corcept Therapeutics has a consensus target price of $88.83, indicating a potential upside of 3.41%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.84
Corcept Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals0.66% 14.56% 5.25%
Corcept Therapeutics 6.14%7.40%5.76%

In the previous week, Corcept Therapeutics had 4 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 13 mentions for Corcept Therapeutics and 9 mentions for Jazz Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.55 beat Jazz Pharmaceuticals' score of 0.41 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Corcept Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Corcept Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.27B3.49-$356.15M-$0.02N/A
Corcept Therapeutics$761.41M12.11$99.65M$0.35245.43

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 32.70%. Corcept Therapeutics has a consensus price target of $88.83, indicating a potential upside of 3.41%. Given Supernus Pharmaceuticals' higher possible upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Corcept Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$718.95M3.82-$38.55M-$0.51N/A
Corcept Therapeutics$761.41M12.11$99.65M$0.35245.43

Supernus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

93.6% of Corcept Therapeutics shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals-3.74% 13.07% 9.66%
Corcept Therapeutics 6.14%7.40%5.76%

In the previous week, Corcept Therapeutics had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 13 mentions for Corcept Therapeutics and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.89 beat Corcept Therapeutics' score of 0.55 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CORT vs. The Competition

Export
MetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.86B$3.05B$7.05B$12.61B
Dividend YieldN/A2.06%2.68%8.00%
P/E Ratio245.4419.1727.1124.26
Price / Sales12.11838.79589.96117.88
Price / Cash101.7856.8029.2249.36
Price / Book13.944.2210.746.29
Net Income$99.65M$64.26M$3.58B$330.66M
7 Day Performance-8.66%-3.58%-2.11%-1.35%
1 Month Performance3.61%2.12%3.27%-0.64%
1 Year Performance18.04%20.35%26.31%19.08%

Corcept Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CORT
Corcept Therapeutics
2.4756 of 5 stars		$85.90
-6.5%		$88.83
+3.4%		+19.5%$9.86B$761.41M245.44300
ANVS
Annovis Bio
3.4449 of 5 stars		$1.97
+2.3%		$11.67
+493.7%		-35.8%$66.52MN/AN/A3
RPRX
Royalty Pharma
4.3339 of 5 stars		$58.37
+1.0%		$53.71
-8.0%		+57.5%$33.28B$2.38B39.7180
ZTS
Zoetis
4.9716 of 5 stars		$75.06
-1.6%		$123.46
+64.5%		-51.3%$31.98B$9.47B12.4514,500
JAZZ
Jazz Pharmaceuticals
3.6904 of 5 stars		$248.25
+0.2%		$245.94
-0.9%		+114.9%$15.56B$4.27BN/A2,890

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Forget SpaceX, this is Elon’s Next Breakthrough
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel